The phytochemical piceatannol induces the loss of CBL and CBL-associated proteins

Molecular Cancer Therapeutics

Volumn 8, Issue 3, 2009, Pages 602-614

  Klimowicz, Alexander C ^a   Bisson, Sabine A ^a,b   Hans, Karm ^a   Long, Elizabeth M ^a   Hansen, Henrik C ^a,c   Robbins, Stephen M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Resverlogix Corp   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOQUINONE DERIVATIVE; CATECHOL DERIVATIVE; CBL PROTEIN; PICEATANNOL; RESVERATROL; 3,3',4,5'-TETRAHYDROXYSTILBENE; ANTINEOPLASTIC AGENT; CBLB PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STILBENE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; EMBRYO; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CELL STRAIN 3T3; CELL STRAIN K 562; DRUG EFFECT; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; PATHOLOGY; PROTEIN BINDING; PROTEIN PROCESSING;

3T3 CELLS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELLS, CULTURED; HUMANS; K562 CELLS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-CBL; SIGNAL TRANSDUCTION; STILBENES;

EID: 66449135699     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0891     Document Type: Article

References (50)

1. Ferrigni NR, McLaughlin JL, Powell RG, Smith CR, Jr. Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 1984;47:347-352 (Pubitemid 14124704)
2. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB. Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation. J Immunol 2002;169:6490-6497 (Pubitemid 36903500)
3. Dang O, Navarro L, David M. Inhibition of lipopolysaccharide-induced interferon regulatory factor 3 activation and protection from septic shock by hydroxystilbenes. Shock 2004;21:470-475
4. Matsuda H, Tewtrakul S, Morikawa T, Yoshikawa M. Anti-allergic activity of stilbenes from Korean rhubarb (Rheum undulatum L.): structure requirements for inhibition of antigen-induced degranulation and their effects on the release of TNF-α and IL-4 in RBL-2H3 cells. Bioorg Med Chem 2004;12:4871-4876 (Pubitemid 39164395)
5. Seow CJ, Chue SC, Duan W, Yeo KS, Koh AH, Wong WS. Effects of inhibitors of the tyrosine signaling cascade on antigen challenge of guinea pig airways in vitro. Ann Acad Med Singapore 2004;33:S41-3.
6. Wieder T, Prokop A, Bagci B, et al. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 2001;15:1735-1742 (Pubitemid 33061841)
7. Larrosa M, Tomas-Barberan FA, Espin JC. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr 2004;43:275-284 (Pubitemid 39377761)
8. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004;3:11-20. (Pubitemid 39193674)
9. Geahlen RL, McLaughlin JL. Piceatannol (3,4,3′,5′- tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 1989;165:241-245
10. Thakkar K, Geahlen RL, Cushman M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J Med Chem 1993;36:2950-2955 (Pubitemid 23315399)
11. 3 signaling in platelets. Blood 1999;93:2645-2652
12. Wang BH, Lu ZX, Polya GM. Inhibition of eukaryote serine/threonine- specific protein kinases by piceatannol. Planta Med 1998;64:195-199 (Pubitemid 28184002)
13. Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005;175:3339-3346 (Pubitemid 41170555)
14. Gledhill JR, Walker JE. Inhibition sites in F1-ATPase from bovine heart mitochondria. Biochem J 2005;386:591-598 (Pubitemid 40445885)
15. 1 complex. Biochem Biophys Res Commun 1999;261:499-503.
16. Azmi AS, Bhat SH, Hadi SM. Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett 2005;579:3131-3135 (Pubitemid 40797847)
17. Cavalieri EL, Li KM, Balu N, et al. Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 2002;23:1071-1077 (Pubitemid 34752965)
18. Hirakawa K, Oikawa S, Hiraku Y, Hirosawa I, Kawanishi S. Catechol and hydroquinone have different redox properties responsible for their differential DNA-damaging ability. Chem Res Toxicol 2002;15:76-82. (Pubitemid 34106092)
19. Ovesna Z, Kozics K, Bader Y, et al. Antioxidant activity of resveratrol, piceatannol and 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene in three leukemia cell lines. Oncol Rep 2006;16:617-624
20. Waffo Teguo P, Fauconneau B, Deffieux G, Huguet F, Vercauteren J, Merillon JM. Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from Vitis vinifera cell cultures. J Nat Prod 1998;61:655-657 (Pubitemid 28262038)
21. Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001;2:294-307. (Pubitemid 33676972)
22. Yokouchi M, Kondo T, Sanjay A, et al. Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J Biol Chem 2001;276:35185-35193 (Pubitemid 37384527)
23. Howlett CJ, Robbins SM. Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated cellular transformation. Oncogene 2002;21:1707-1716 (Pubitemid 34259034)
24. Magnifico A, Ettenberg S, Yang C, et al. WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J Biol Chem 2003;278:43169-43177 (Pubitemid 37345936)
25. Bisson SA, Ujack EE, Robbins SM. Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line. Oncogene 2002;21:3677-3687 (Pubitemid 34620531)
26. Andoniou CE, Lill NL, Thien CB, et al. The Cbl proto-oncogene product negatively regulates the Src-family tyrosine kinase Fyn by enhancing its degradation. Mol Cell Biol 2000;20:851-867 (Pubitemid 30044222)
27. Wong H, Anderson WD, Cheng T, Riabowol KT. Monitoring mRNA expression by polymerase chain reaction: the "primer-dropping" method. Anal Biochem 1994;223:251-258
28. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC III. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci U S A 1989;86:1168-1172 (Pubitemid 19061515)
29. Andoniou CE, Thien CB, Langdon WY. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J 1994;13:4515-4523 (Pubitemid 24310201)
30. Widmann C, Gibson S, Johnson GL. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem 1998;273:7141-7147 (Pubitemid 28160387)
31. Ribon V, Hubbell S, Herrera R, Saltiel AR. The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner. Mol Cell Biol 1996;16:45-52. (Pubitemid 126506949)
32. Boekelheide K, Graham DG, Mize PD, Anderson CW, Jeffs PW. Synthesis of γ-L-glutaminyl-[3,5-3H]4-hydroxybenzene and the study of reactions catalyzed by the tyrosinase of Agaricus bisporus. J Biol Chem 1979;254:12185-12191 (Pubitemid 10143689)
33. Boekelheide K, Graham DG, Mize PD, Jeffs PW. The metabolic pathway catalyzed by the tyrosinase of Agaricus bisporus. J Biol Chem 1980;255:4766-4771
34. Boatman RJ, English JC, Perry LG, Fiorica LA. Covalent protein adducts of hydroquinone in tissues from rats: identification and quantitation of sulfhydryl-bound forms. Chem Res Toxicol 2000;13:853-860
35. Waidyanatha S, Yeowell-O'Connell K, Rappaport SM. A new assay for albumin and hemoglobin adducts of 1,2- and 1,4-benzoquinones. Chem Biol Interact 1998;115:117-139 (Pubitemid 28403587)
36. Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997;324:1-18. (Pubitemid 27229359)
37. Sugumaran M, Dali H, Semensi V. Mechanistic studies on tyrosinase-catalysed oxidative decarboxylation of 3,4-dihydroxymandelic acid. Biochem J 1992;281:353-357
38. Ahlfors SR, Sterner O, Hansson C. Reactivity of contact allergenic haptens to amino acid residues in a model carrier peptide, and characterization of formed peptide-hapten adducts. Skin Pharmacol Appl Skin Physiol 2003;16:59-68. (Pubitemid 36173471)
39. Brennan P, O'Neill LA. Inhibition of nuclear factor κB by direct modification in whole cells-mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem Pharmacol 1998;55:965-973
40. Lopachin RM, Barber DS, Geohagen BC, Gavin T, He D, Das S. Structure-toxicity analysis of type-2 alkenes: in vitro neurotoxicity. Toxicol Sci 2007;95:136-146 (Pubitemid 44942784)
41. Moos PJ, Edes K, Mullally JE, Fitzpatrick FA. Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004;25:1611-1617 (Pubitemid 39214303)
42. Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H. αβ-Unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J Biol Chem 2005;280:14145-14153 (Pubitemid 40517317)
43. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295 (Pubitemid 36554699)
44. Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006;11:274-284
45. Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci U S A 2004;101:17456-17461 (Pubitemid 39657426)
46. Baysan A, Yel L, Gollapudi S, Su H, Gupta S. Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 2007;30:313-318
47. Davis W, Jr., Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther 2001;296:1-6. (Pubitemid 32015053)
48. Engel RH, Evens AM. Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 2006;11:300-312 (Pubitemid 43253493)
49. Ge Y, Montano I, Rustici G, et al. Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood 2006;108:4126-4135 (Pubitemid 44913284)
50. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-33723 (Pubitemid 37553204)